• Rebecca Riggins' profile

    • What I do

    • Affiliations

      Current

    • Interests

      For the past 4 years, I have been a member of Dr. Robert Clarke’s laboratory in the Department of Oncology and Lombardi Comprehensive Cancer Center at Georgetown University. Our group is primarily interested in studying the cellular and molecular mechanisms of hormone independence and therapeutic resistance in breast cancer. Most of the lab studies endocrine therapies, although there is one project that focuses on acquired resistance to conventional cytotoxic agents such as anthracyclines and the taxanes. Another significant area of focus in the lab, which complements our in vitro studies, is molecular profiling of breast tumors, with the aim of understanding cancer signaling pathways as well as learning how to identify and predict phenotypes with respect to drug resistance.

      While I am still very much a part of Robert’s lab, I am somewhat in transition. I was recently promoted to Assistant Professor on the Research Track. I’ve become especially interested in a particular histologic subtype of breast cancer (invasive lobular carcinoma), and a family of orphan nuclear receptors that appear to be involved in regulating cell proliferation and hormone response in these types of breast cancers.

    • Projects

      Rebecca Riggins has not yet listed any projects.

    • Publications

      • Bouker K, Skaar T, Harburger D, Riggins R, Fernandez D, Zwart A, Clarke R. The A4396G polymorphism in interferon regulatory factor 1 is frequently expressed in breast cancer cell lines. Cancer genetics and cytogenetics 175 (1) , 61-4 (2007) PubMed ID:(17498560)

      • Gomez B, Riggins R, Shajahan A, Klimach U, Wang A, Crawford A, Zhu Y, Zwart A, Wang M, Clarke R. Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 21 (14) , 4013-27 (2007) (Epub 27 Jul 2007) PubMed ID:(17660348)

      • Riggins R, Schrecengost R, Guerrero M, Bouton A. Pathways to tamoxifen resistance. Cancer letters 256 (1) , 1-24 (2007) (Epub 01 May 2007) PubMed ID:(17475399)

      • Schrecengost R, Riggins R, Thomas K, Guerrero M, Bouton A. Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane ruffling. Cancer research 67 (13) , 6174-82 (2007) PubMed ID:(17616674)

      • Riggins R, Thomas K, Ta H, Wen J, Davis R, Schuh N, Donelan S, Owen K, Gibson M, Shupnik M, Silva C, Parsons S, Clarke R, Bouton A. Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer research 66 (14) , 7007-15 (2006) PubMed ID:(16849545)

      view all
Sign in

New to Nature Network?
Sign up today!

Search people
Send an invite

Advertisement